PRGO.TA - Perrigo Company plc

Tel Aviv - Tel Aviv Delayed Price. Currency in ILS
18,250.00
+470.00 (+2.64%)
As of 4:24PM IDT. Market open.
Stock chart is not supported by your current browser
Previous Close17,780.00
Open18,150.00
Bid18,250.00 x 7100
Ask18,260.00 x 29700
Day's Range18,120.00 - 18,320.00
52 Week Range13,730.00 - 29,760.00
Volume40,562
Avg. Volume124,256
Market Cap2.543T
Beta (3Y Monthly)1.37
PE Ratio (TTM)21,856.29
EPS (TTM)0.83
Earnings DateN/A
Forward Dividend & Yield3.03 (1.71%)
Ex-Dividend Date2019-05-30
1y Target Est86.00
  • Perrigo Completes Divestiture of Animal Health Business for $185 Million
    PR Newswire14 days ago

    Perrigo Completes Divestiture of Animal Health Business for $185 Million

    TASE: PRGO) today announced that it has completed the previously announced divestiture of its Animal Health business to PetIQ (PETQ) for $185 million. Perrigo CEO and President Murray S. Kessler stated, "Completing the divestiture of the Animal Health business is an important step in the transformation of Perrigo into a consumer-focused self-care company.

  • GlobeNewswire14 days ago

    PetIQ, Inc. Completes Acquisition of Perrigo Animal Health

    EAGLE, Idaho, July 08, 2019 -- PetIQ, Inc. (“PetIQ” or the “Company”) (Nasdaq: PETQ), a leading pet medication and wellness company, today announced effective today, it has.

  • Perrigo Announces FDA Final Approval and Launch Of The AB-rated Generic Version Of Metrogel-Vaginal® Gel
    PR Newswire19 days ago

    Perrigo Announces FDA Final Approval and Launch Of The AB-rated Generic Version Of Metrogel-Vaginal® Gel

    TASE: PRGO) today announced its product development partner received final approval from the U.S. Food and Drug Administration for its AB-rated Abbreviated New Drug Application ("ANDA") referencing Metrogel-Vaginal® (metronidazole vaginal gel 0.75%).  Perrigo will acquire full ownership of the ANDA under a pre-existing arrangement with its partner within 30 days and anticipates launching this product immediately thereafter. The product is manufactured by Perrigo and was developed through its partnership with Capstone Development Solutions, a company of Water Street Healthcare Partners, a strategic investor focused exclusively on the health care industry. Perrigo Executive Vice President and President Rx Pharmaceuticals, Sharon Kochan stated, "This launch exemplifies Perrigo's commitment to developing and launching products within the extended topicals category.

  • Benzinga20 days ago

    Perrigo Adjusts Guidance After Acquiring Ranir Global For $750M

    Perrigo Company (NYSE: PRGO ) has acquired Ranir Global Holdings, a supplier of oral self-care products for $750 million in cash. Perrigo also adjusted its FY2019 earnings guidance, from $3.75-$4.05 including ...

  • PR Newswire20 days ago

    Perrigo Completes Acquisition Of Ranir, Raises Guidance

    - Advances transformation to a consumer-focused, self-care company - Raises 2019 non-GAAP ("adjusted") diluted EPS guidance to between $3.75 - $4.05 (1), which includes accretion of $0.10 from ...

  • Perrigo Announces FDA Final Approval For AB Rated Generic Version Of Voltaren® Gel 1%
    PR Newswire2 months ago

    Perrigo Announces FDA Final Approval For AB Rated Generic Version Of Voltaren® Gel 1%

    TASE: PRGO) today announced its partner received final approval from the U.S. Food and Drug Administration for its AB rated Abbreviated New Drug Application (ANDA) referencing Voltaren® Gel, 1% (diclofenac sodium topical gel, 1%). Perrigo will acquire full ownership of the ANDA under a pre-existing arrangement with its partner within 30 days. Perrigo will manufacture diclofenac sodium topical gel 1% in its plant in Israel.

  • Reuters2 months ago

    US STOCKS-Wall St falls as weak economic data triggers growth worries

    U.S. stocks fell on Wednesday, as a clutch of weak economic data from the United States and China sparked worries of slowing global growth against the backdrop of a bitter trade dispute that has roiled financial markets. Domestic data showed retail sales unexpectedly fell in April as households cut back on purchases of motor vehicles and a range of other goods, and another report showed declining output of cars and machinery led to a surprise fall in U.S. factory production for April. Meanwhile data from China also showed surprisingly weak growth in retail sales and industrial output for April, adding pressure on the country to roll out more stimulus.

  • Reuters2 months ago

    US STOCKS-Wall St set to open lower after weak retail sales data

    Wall Street was set to open lower on Wednesday, as a surprise fall in domestic retail sales and underwhelming data from China raised growth concerns, while investors waited for more developments on the U.S.-China trade dispute. Government data showed U.S. retail sales unexpectedly fell in April as motor vehicle purchases slumped, while data from China also showed surprisingly weak growth in retail sales and industrial output for April, adding pressure on Beijing to roll out more stimulus. "The U.S. retail sales report is clearly disappointing.

  • Barrons.com2 months ago

    It’s a Brutal Day for the Market but These 8 Stocks Are Thriving

    FEATURE The S&P 500 was getting hammered this morning amid continued trade fears. Many of the 500 stocks in the index were down Thursday morning, dragging the index down as low as 1.5%. But not every stock was losing.

  • TheStreet.com2 months ago

    Perrigo Buys Oral Care Company Ranir for $750 Million as Part of New Strategy

    was gaining more than 5% Thursday after announcing the all-cash acquisition of privately-held Ranir Global Holdings in a deal valued at $750 million. Ranir is the largest private label oral care company in the world, according to Perrigo, with a portfolio of more than 300 oral care products including toothbrush heads and whitening strips. "The addition of Ranir to the Perrigo family illustrates a key component of our new strategy, accelerating growth by pursuing adjacent self-care categories.

  • Perrigo Unveils Self-Care Transformation Plan, 2019 Guidance And Long-Term Growth Targets At Investor Day
    PR Newswire2 months ago

    Perrigo Unveils Self-Care Transformation Plan, 2019 Guidance And Long-Term Growth Targets At Investor Day

    Chief Executive Officer and President Murray S. Kessler, along with several key members of his leadership team, will share the Company's strategic plan, vision, and financial objectives while introducing their priorities for transforming Perrigo from a healthcare company to a consumer self-care company. Kessler commented, "We have begun the process of transformation to recapture what we call 'The Perrigo Advantage'. The team has been hard at work during my first six months as CEO, analyzing our challenges and most importantly, building actionable plans to reinvent the company.

  • PR Newswire2 months ago

    Global Oral Care Leader Ranir® Agrees to be Acquired by Leading Global Self-Care Company Perrigo

    Combines Two Consumer-Focused Self-Care Companies Dedicated to Meeting Customer Needs; Expands Ability to Deliver Millions of Affordable Healthy Smiles Worldwide GRAND RAPIDS, Mich. , May 9, 2019 /PRNewswire/ ...

  • Perrigo To Expand Into Adjacent Self-Care Category By Acquiring Ranir Global Holdings LLC, The Leading Global Private Label Supplier Of Oral Self-Care Products
    PR Newswire2 months ago

    Perrigo To Expand Into Adjacent Self-Care Category By Acquiring Ranir Global Holdings LLC, The Leading Global Private Label Supplier Of Oral Self-Care Products

    DUBLIN, May 9, 2019 /PRNewswire/ -- Perrigo Company plc (NYSE, TASE: PRGO) today announced that it has reached a definitive agreement to purchase privately-held Ranir Global Holdings LLC ("Ranir") in a transaction valued at $750 million on a cash-free, debt-free basis, or approximately $685 million net of cash tax benefits on a present value basis. Ranir is the largest private label oral care company globally, with a comprehensive portfolio of 300+ highly customized oral care solutions including power toothbrush heads, power toothbrush handles, whitening strips, manual toothbrushes, floss, dentures and travel kits that it sells into over 50 countries worldwide.

  • PetIQ, Inc. (PETQ) Q1 2019 Earnings Call Transcript
    Motley Fool2 months ago

    PetIQ, Inc. (PETQ) Q1 2019 Earnings Call Transcript

    PETQ earnings call for the period ending March 31, 2019.

  • Associated Press2 months ago

    Perrigo: 1Q Earnings Snapshot

    The Dublin-based company said it had net income of 47 cents per share. Earnings, adjusted for one-time gains and costs, came to $1.07 per share. The results beat Wall Street expectations. The average estimate ...

  • Perrigo Company plc Reports First Quarter 2019 Financial Results, Begins Consumer Self-Care Transformation
    PR Newswire2 months ago

    Perrigo Company plc Reports First Quarter 2019 Financial Results, Begins Consumer Self-Care Transformation

    DUBLIN , May 8, 2019 /PRNewswire/ --  GAAP ("reported") net sales were $1.2 billion , reflecting a 4% decline versus the prior year period, or down 1% excluding the unfavorable impact of currency. ...

  • Perrigo To Divest Animal Health Business For $185 Million In Cash As Part Of Consumer Self-Care Transformation
    PR Newswire2 months ago

    Perrigo To Divest Animal Health Business For $185 Million In Cash As Part Of Consumer Self-Care Transformation

    TASE: PRGO), today announced that it has reached a definitive agreement to sell its Animal Health business to PetIQ (PETQ) in a transaction valued at $185 million in cash. Perrigo CEO and President Murray S. Kessler commented, "We are pleased to have reached an agreement with PetIQ on selling our Animal Health business and look forward to working with them to ensure a seamless transition. In calendar year 2018, Perrigo realized $94 million in net sales and $0.08 of adjusted diluted EPS from the Animal Health business.

  • GlobeNewswire2 months ago

    PetIQ, Inc. Reports Record First Quarter 2019 Financial Results

    First Quarter 2019 Net Sales Increased 29% Year-Over-Year to $148.4 MillionReiterates Full Year 2019 Outlook Enters Into Definitive Agreement to Acquire Perrigo Animal Health.

  • Perrigo Announces First Quarter Calendar Year 2019 Earnings Date And Upcoming Conference Participation
    PR Newswire3 months ago

    Perrigo Announces First Quarter Calendar Year 2019 Earnings Date And Upcoming Conference Participation

    TASE: PRGO), today announced that it will release its first quarter calendar year 2019 financial results on May 8, 2019 after market close in the U.S. and will discuss the results and 2019 guidance at its Investor Day on May 9, 2019. The company also announced that Perrigo President and Chief Executive Officer, Murray S. Kessler, will present at the 2019 Goldman Sachs Global Staples Forum at 2:00 PM EDT on Tuesday, May 14, 2019. Perrigo Company is dedicated to making lives better by bringing "Quality, Affordable Self-care Products™" that consumers trust everywhere they are sold.  The Company is a leading provider of over-the-counter health and wellness solutions that enhance individual well-being by empowering consumers to proactively prevent or treat conditions that can be self-managed.  Visit Perrigo online at (http://www.perrigo.com).

  • TheStreet.com3 months ago

    IRS Has Wrong Prescription for Perrigo

    tumbled 7.3% to $47.67 Tuesday after the pharmaceutical company said it had received an $843 million bill from the Internal Revenue Service. The Dublin-based company said in a filing that it had gotten a revised Notice of Proposed Adjustment from the IRS examination team auditing Athena Neurosciences Inc. for the years ended Dec. 31, 2011 - 2013. Athena was acquired as a U.S. subsidiary by Elan Corp. in 1996 and Perrigo acquired Elan through a December 2013 business combination between Perrigo's predecessor and Elan.

  • Perrigo Increases Its Dividend By 11%
    PR Newswire3 months ago

    Perrigo Increases Its Dividend By 11%

    TASE: PRGO), today announced that the company's Board of Directors, consistent with its recently approved strategic plan to evolve to a consumer self-care company, approved an 11% increase to the company's quarterly dividend to $0.21 per share from $0.19 per share. This dividend increase marks the 16th consecutive year Perrigo has increased its dividend. Perrigo Company is dedicated to making lives better by bringing "Quality, Affordable Self-care Products™" that consumers trust everywhere they are sold. The Company is a leading provider of over-the-counter health and wellness solutions that enhance individual well-being by empowering consumers to proactively prevent or treat conditions that can be self-managed. Visit Perrigo online at (http://www.perrigo.com).

  • Perrigo To Host Investor Day
    PR Newswire3 months ago

    Perrigo To Host Investor Day

    The event will feature presentations from Murray S. Kessler, President and Chief Executive Officer, as well as members of the Company's leadership team. Perrigo Company is dedicated to making lives better by bringing "Quality, Affordable Self-care Products™" that consumers trust everywhere they are sold.  The Company is a leading provider of over-the-counter health and wellness solutions that enhance individual well-being by empowering consumers to proactively prevent or treat conditions that can be self-managed.  Visit Perrigo online at (http://www.perrigo.com). Certain statements in this press release are "forward-looking statements." These statements relate to future events or the Company's future financial performance and involve known and unknown risks, uncertainties and other factors that may cause the actual results, levels of activity, performance or achievements of the Company or its industry to be materially different from those expressed or implied by any forward-looking statements.

  • Perrigo Announces Tentative FDA Approval For The Generic Version Of Sernivo® Spray, 0.05%
    PR Newswire4 months ago

    Perrigo Announces Tentative FDA Approval For The Generic Version Of Sernivo® Spray, 0.05%

    TASE: PRGO), a leading global provider of "Quality, Affordable, Self-Care Products™", today announced it has received tentative approval from the U.S. Food and Drug Administration for the generic version of Sernivo® (betamethasone dipropionate) Spray 0.05%. Perrigo previously settled its Hatch-Waxman litigation relating to Sernivo® (betamethasone dipropionate) Spray 0.05% brought by Promius Pharma LLC. Terms of the settlement remain confidential. Perrigo Executive Vice President and President Rx Pharmaceuticals Sharon Kochan stated, "Today's announcement marks our second tentative approval this year, in addition to four previously approved abbreviated new drug applications received in 2019.

  • Perrigo Announces Patent Litigation Settlement For The Generic Version Of Finacea® Foam, 15%
    PR Newswire4 months ago

    Perrigo Announces Patent Litigation Settlement For The Generic Version Of Finacea® Foam, 15%

    Perrigo Executive Vice President and President Rx Pharmaceuticals Sharon Kochan stated, "This settlement is another example of our long-term commitment and investments in our extended topicals strategy. Perrigo Company is dedicated to making lives better by bringing high "Quality, Affordable Self-care Products™" that consumers trust everywhere they are sold.  The Company is a leading provider of over-the-counter health and wellness solutions that enhance individual well-being by empowering consumers to proactively prevent or treat conditions that can be self-managed.  Visit Perrigo online at (http://www.perrigo.com). Certain statements in this press release are "forward-looking statements." These statements relate to future events or the Company's future financial performance and involve known and unknown risks, uncertainties and other factors that may cause the actual results, levels of activity, performance or achievements of the Company or its industry to be materially different from those expressed or implied by any forward-looking statements.